10:04pm Monday 11 November 2019

Teaching neurons to respond to placebos as potential treatment for Parkinson's

They found that it is possible to turn a neuron which previously hasn’t responded to placebos (placebo ‘non-responder’ neuron) into a placebo ‘responder’ by conditioning Parkinson patients with apomorphine, a dopaminergic drug used in the treatment of Parkinson’s disease (PD).

When a placebo (saline solution) was given for the first time, it induced neither clinical benefit nor associated neuronal changes in the thalamus, a brain region known to be involved in PD. However, if repeated administrations of apomorphine were performed before placebo administration, a placebo was capable of increasing thalamus neuronal activity along with clinical improvement (reduction of muscle rigidity). Interestingly, the higher the previous administrations of apomorphine was, the larger the neuronal changes and the clinical improvement. When apomorphine was administered for 4 days in a row, the subsequent administration of a placebo induced a response that was as large as the one induced by apomorphine. These changes lasted for 24 hours.

The researchers administered apomorphine, either 1, 2, 3 or 4 days before the surgical implantation of electrodes for deep brain stimulation, which is an effective treatment for PD. During surgery, they replaced apomorphine with a placebo and recorded from single neurons in the thalamus along with the assessment of muscle rigidity of the arm.

Fabrizio Benedetti, from the Department of Neuroscience at University of Turin Medical School, Italy and first author of the study, explained,

‘These findings show that is possible to teach neurons in the thalamus to respond to placebos, so that a placebo non-responder can be turned into a placebo responder. These findings may have profound implications and applications, because we can reduce drug intake by exploiting these learning mechanisms. Since this study shows that there is a memory for drug action, the alternate administration drug-placebo-drug- placebo etc. means people would need to take less medication but yet obtain the same clinical benefit.

‘If a placebo is given after four previous administrations of apomorphine, the placebo response can be as large as the drug response, and this effect lasts up to 24 hours. Therefore, a future challenge will be to see whether this effect can be extended beyond 24 hours.’

Notes to Editors

    Full paper title: Benedetti F et al (2016) Teaching neurons to respond to placebos. DOI: 10.1113/JP271322 http://onlinelibrary.wiley.com/doi/10.1113/JP271322/full
    The Journal of Physiology publishes advances in physiology, which increase our understanding of how our bodies function in health and disease. http://jp.physoc.org
    The Physiological Society brings together over 3,500 scientists from over 60 countries. The Society promotes physiology with the public and parliament alike. It supports physiologists by organising world-class conferences and offering grants for research and also publishes the latest developments in the field in its three leading scientific journals, The Journal of Physiology, Experimental Physiology and Physiological Reports. www.physoc.org

For further information please contact Dr Helga Groll, Media and Communications Officer.
Telephone: +44 (0)20 7269 5727 or email pressoffice@physoc.org.

The Physiological Society

The Physiological Society is a company limited by guarantee. Registered in England and Wales, No. 323575. Registered Office: Hodgkin Huxley House, 30 Farringdon Lane, London, EC1R 3AW, UK. Registered Charity No. 211585.

The Physiological Society and The Physiological Society logo and The Journal of Physiology and The Journal of Physiology logo are trade marks belonging to The Physiological Society and are registered in the UK and in the EU Community respectively.

Share on:

MORE FROM Brain Diseases

Health news